Navigating Government Pricing for Cell & Gene Therapies

The wave of FDA-approved cell and gene therapies (CGT) is transforming treatment options for diseases that once had few solutions. As more CGTs move from clinical trial to commercial approval and availability, navigating the complexities of government pricing becomes a critical hurdle for emerging manufacturers.